Search - tctmd.com

Displaying 1 - 20 of 98

Sort: Relevancy | Date

The Biggest News of 2018: TCTMD’s Top 10

News Daily News

The Biggest News of 2018: TCTMD’s Top 10

December 31, 2018

Top News in Policy & Practice: 2018

News Features

Top News in Policy & Practice: 2018

December 28, 2018

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

News Daily News

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

December 18, 2018

Better TAVR Outcomes With More Experienced Operators: New York Database

News Daily News

Better TAVR Outcomes With More Experienced Operators: New York Database

Michael O'Riordan

December 12, 2018

Apps? Wearables? Probing Mobile Tech’s Potential to Boost Cardiac Rehab

News Conference News WCC 2018

Apps? Wearables? Probing Mobile Tech’s Potential to Boost Cardiac Rehab

December 07, 2018

Bruises and Bumps: How Cardiology Meetings Survived the End of Direct Industry Sponsorship in Europe

News Features

Bruises and Bumps: How Cardiology Meetings Survived the End of Direct Industry Sponsorship in Europe

November 30, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

November 30, 2018

Are the Best Hospitals Actually the Best? Analysis Looks at US News & World Report Rankings

News Daily News

Are the Best Hospitals Actually the Best? Analysis Looks at US News & World Report Rankings

Yael L. Maxwell

November 28, 2018

News Opinion Conversations in Cardiology

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

November 16, 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

November 15, 2018

Mortality Outcomes Similar Whether TAVR Performed in Hybrid OR or Cath Lab

News Daily News

Mortality Outcomes Similar Whether TAVR Performed in Hybrid OR or Cath Lab

Yael L. Maxwell

November 14, 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

News Conference News AHA 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

November 10, 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

November 10, 2018

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

News Conference News VIVA 2018

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

November 09, 2018

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

Low Incidence of A-fib Seen in Elite Athletes, Including Runners and Triathletes

News Daily News

Low Incidence of A-fib Seen in Elite Athletes, Including Runners and Triathletes

Michael O'Riordan

November 02, 2018

Novel Interatrial Shunt Shows Promise at 1 Year in HF Patients With Reduced and Preserved EF

News Daily News

Novel Interatrial Shunt Shows Promise at 1 Year in HF Patients With Reduced and Preserved EF

November 02, 2018

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

News Daily News

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

November 01, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.